My colleague at FTI has a New White Paper Surveys Healthcare Leaders on Expected Trends in 2022. The data comes from a survey of 251 senior decision makers working in business
Some key findings from communications, investor relations, public affairs, business development, R&D, and marketing for U.S. healthcare and life sciences companies:

drug pricing

More than two-thirds (69%) of respondents expect a Biden administration to make major policy changes to drug pricing in the next 12 months.

reputation

diversity

make a deal

Transaction volumes are expected to increase in 2022. Healthcare IPO activity is expected to increase the most, with 65% (up 12% since 2020) expected to be even higher in 2022,
A quarter (24%) expect it to be “much higher”.Nearly seven in 10 (65%) expect M&A activity to increase in 2022, up 5% from last year, and the majority (57%) also expect an increase in SPACs
The 2022 activity exceeds the previous 12 months.

Hybrid and face-to-face workplace

78% are optimistic when planning a return to the workplace
A workable balance can be found. However, companies are divided on approach,
49% plan to offer hybrid work styles, while 43% are considering returning to pre-pandemic jobs.